XML 19 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Compensatory Equity Incentive Plan and Other Equity Incentives (Tables)
6 Months Ended
Dec. 31, 2013
Compensatory Equity Incentive Plan And Other Equity Incentives Tables  
Schedule of Share Based Compensation Award Plans

These two plans are summarized below:

 

       Award Shares   Available for 
   Award    Outstanding at    Issuance at  
   Shares Authorized   December 31, 2013   December 31, 2013 
          
Equity Compensation Arrangement            
Amended and Restated Omnibus Incentive Plan   2,715,625    1,507,458    569,103 
Employee Stock Purchase Plan   200,000        105,918 
                
    2,915,625    1,507,458    675,021 

 

Schedule of Fair Value Assumptions for Grant Date Value

For stock options granted in the six month periods ended December 31, 2013 and 2012, the Company estimated the fair value of each stock option as of the date of grant using the following assumptions:

 

   Six Months Ended   Six Months Ended 
   December 31, 2013   December 31, 2012 
Expected volatility   118%   110%
Weighted average expected volatility   118%   110%
Dividend yields   0%   0%
Risk-free interest rate   2.48%   0.67%
Expected term, in years   11.85    6.25 

 

Schedule of Share Based Compensation Awards Activity

A summary of the activity for share-based compensation awards in the six months ended December 31, 2013 is presented below:

 

 

               Restricted 
   Stock Options   Stock Units (RSUs) 
       Weighted   Weighted       Weighted 
       Average   Average       Average 
       Exercise   Remaining       Remaining 
       Price   Contract       Contract 
   Shares   (per share)   Life (YRS)   Shares   Life (YRS) 
June 30, 2013   585,009   $2.38    5.9    834,700    1.1 
                          
Granted   80,000    1.41    9.8    212,760    2.8 
Exercised               (191,160)    
Cancelled   (13,851)   2.40             
                          
December 31, 2013   651,158   $2.26    6.0    856,300    1.1 
                          
Awards exercisable/vested as of                         
December 31, 2013   433,408   $2.65    4.7    435,332     
                          
Awards unexercisable/unvested as of                         
December 31, 2013   217,750   $1.46    8.7    420,968    1.1 
    651,158              856,300      

 

Schedule of Share Based Compensation Future Cost to be Recognized

We expect to recognize the compensation cost as follows:

 

       Restricted     
   Stock   Stock     
   Options   Units   Total 
Six months ended June 30, 2014  $29,042   $99,913   $128,955 
Year ended June 30, 2015   41,127    156,625    197,752 
Year ended June 30, 2016   26,784    112,291    139,075 
Year ended June 30, 2017   17,057    20,865    37,922 
Year ended June 30, 2018   3,508        3,508 
   $117,518   $389,694   $507,212 
Schedule of Activity of Unexerciseable and Unvested Awards

The following table is a summary of the number and weighted average grant date fair values regarding the Company’s unexercisable/unvested awards as of December31, 2013 and changes during the six months then ended:

 

Unexercisable/unvested awards  Stock Options   RSU Shares   Total Shares   Weighted-Average Grant Date Fair Values 
June 30, 2013   183,250    371,670    554,920   $1.57 
Granted   80,000    212,760    292,760    1.41 
Vested   (45,500)   (163,462)   (208,962)   1.43 
Cancelled/Forfeited                
December 31, 2013   217,750    420,968    638,718   $1.19 

 

Schedule of Financial Statement Effect Related to Share Based Compensation

The following table shows total stock-based compensation expense for the six months ended December 31, 2013 and 2012 included in the consolidated statements of operations and comprehensive income:

 

   (Unaudited)   (Unaudited) 
   Six Months Ended   Six Months Ended 
   December 31,   December 31, 
   2013   2012 
         
Stock options   38,857    33,692 
RSU   188,789    94,594 
Total   227,646    128,286 
           
The amounts above were included in:          
General & administrative   221,994    122,292 
Cost of sales       1,580 
New product development   5,651    4,414 
    227,645    128,286